Topelia will initially focus on the development of its TPL101 Antiviral Triple Therapy for coronavirus infection.

Topelia sees a range of potential uses for TPL101 in coronavirus infection. Additional potential applications for TPL101 may include other coronavirus infections, as well as other viral vectors, including the RNA viruses such as Zika virus, dengue fever, yellow fever virus, and West Nile virus, Hendra virus, Newcastle virus, Chikungunya virus, Avian influenza A virus, Porcine Reproductive and Respiratory Syndrome virus, Human immunodeficiency virus type 1 as well as DNA viruses such as Equine herpesvirus type 1 and Pseudorabies virus.